Massivemarkets

SMMT

Summit Therapeutics Inc. Common Stock

Nasdaq · usd

$10.67-1.15 (-9.73%)
At close · 15-minute delayed
$10.64-0.03 (-0.28%)
As of 7:59:30 PM EST on Nov 17, 2026 · After hours

Summit Therapeutics Inc. Common Stock (SMMT) trades at $10.67 (-9.73%) as of 7:59:30 PM EST on Nov 17, 2026, -31.47% over the past month. Market cap is $9.45B, with 9.4 days to cover in short interest.

Stock performance

How Summit Therapeutics Inc. Common Stock (SMMT) stock has performed from one day to one year, with its 52-week range.

-11.33%
-$1.36 over 1D
$10.66$11.10$11.54$11.984:00 AM9:40 AM12:40 PM3:45 PM8:00 PM$10.64
1D
-9.73%
1W
-40.16%
1M
-31.47%
YTD
-38.99%
1Y
-36.53%
52-wk range
$10.53 – $29.23

Key statistics

Today's trading snapshot for SMMT: day range, open, previous close, volume and market cap.

Day range
$10.53 – $11.91
Open
$11.70
Prev close
$11.82
Volume
13.17M
Market cap
$9.45B
Shares out
799.76M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Summit Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
16.74
P/FCF
—
ROE
-147.5%
ROA
-120.2%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 16, 2026

8-K filings

Material corporate events Summit Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • On November 4, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing its financial results and operational progress for the third quarter ended September 30, 2026.

  • Private placementSep 29, 2026

    On September 28, 2026, Summit Therapeutics Inc. entered into a securities purchase agreement with AstraZeneca Holdings B.V. for the issuance and sale of 108,955.3686 shares of newly designated Class A Convertible Preferred Stock at a purchase price of $18,356.14 per share, for aggregate gross proceeds of $2.0 billion. The Preferred Shares and any shares issuable upon conversion will be issued in reliance on the exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D.

  • On September 15, 2026, Summit Therapeutics Inc. issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC 2026).

  • On September 2, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced positive overall survival ("OS") results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression. In this preplanned analysis of OS, a secondary endpoint in HARMONi-2, Akeso reported that ivonescimab monotherapy demonstrated a statistically significant improvement compared to pembrolizumab monotherapy.

  • Akeso reported that, at a pre-specified interim analysis, the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival compared to the durvalumab-based regimen. The study also met the key secondary endpoints of progression-free survival and objective response rate.

SMMT short interest

How heavily SMMT is shorted: shares short, days to cover and average daily volume.

Days to cover
9.4
Short interest
42.26M
Avg volume
4.5M

As of · reported to FINRA twice monthly.

SMMT news

The latest news and headlines about Summit Therapeutics Inc. Common Stock (SMMT).

Frequently asked questions

What is the Summit Therapeutics Inc. Common Stock (SMMT) stock price today?

Summit Therapeutics Inc. Common Stock (SMMT) is trading at $10.67 (-9.73% on the day) as of 7:59:30 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Summit Therapeutics Inc. Common Stock?

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.

What is the short interest in SMMT?

As of Oct 30, 2026, SMMT has 42.26M shares short and 9.4 days to cover.

What exchange is SMMT listed on?

Summit Therapeutics Inc. Common Stock (SMMT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of SMMT with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SMMT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.